BioVaxys Technology

BioVaxys Technology Corp is a biotechnology company that develops antiviral & anticancer vaccine platforms, as well as immuno-diagnostics.In June 2023, BioVaxys Technology Corp sold TAETSoftware Corp to 10402588 BC Ltd.In March 2023, BioVaxys Technology Corp acquired TAETSoftware Corp.In November 2022, BioVaxys Technology Corp had completed a non-brokered private placement of 4,050,000 units at a price of $0.10 per unit for total gross proceeds of $405,000. Later that month, BioVaxys Technology Corp had closed the first tranche of a non-brokered private placement. Pursuant to Tranche 1 of the Private Placement, the Company has issued 940,000 units at a price of $0.125 per Unit for total gross proceeds of $117,500.In October 2022, BioVaxys Technology Corp had settled an aggregate of $300,000 in debt through the issuance of common shares issued at a deemed price of $0.15 per common share. Later that month, the company has agreed to issue common shares at a p